



Cumulative Index to Volume 21

Volume 21

February	VENTRICULAR ASSIST DEVICES AND THE ARTIFICIAL HEART, pages 1-146
May	INFECTIVE ENDOCARDITIS, pages 147-288
August	PREVENTION OF CARDIOVASCULAR DISEASE, pages 289-490
November	CARDIOVASCULAR COMPUTED TOMOGRAPHY, pages 491-673

Note: Page numbers of article titles are in **boldface** type.

A

- Abdominal left ventricular assist device (ALVAD), 3-4
- Aberrant immune activation  
with LVAD implantation  
systemic consequences of, 129-132
- Aberrant T-cell activation  
LVAD surface result in  
monocyte-T-cell interactions on, 129
- AbioCor, 9, 121-124  
described, 122  
external components of, 122-123  
historical background of, 121-122  
indications for, 123  
internal components of, 122  
patient-carried electronics in, 123  
studies of, 123-124
- AbioCor TAH  
as destination therapy, 70
- ABIOMED BVS 5000 VAD, 6, 38-40
- Abscess(es)  
metastatic  
infective endocarditis and, 278  
paravalvular  
infective endocarditis and, 274-275
- Abuse  
drug  
as factor in surgical treatment for infective endocarditis, 248-249
- Abuser(s)  
drug  
IV  
infective endocarditis in, **167-176**. See also *Infective endocarditis, in IV drug abusers*.
- ACE inhibitors. See *Angiotensin-converting enzyme (ACE) inhibitors*.
- Activity(ies)  
in outpatient management of patients on long-term assist devices, 102
- Acute cardiogenic shock  
management of, **43-50**. See also *Cardiogenic shock, acute, management of*.
- Acute coronary syndromes  
thrombosis in, 303
- Acute fulminant myocarditis  
short-term VADs for, 79
- Acute peripheral vascular occlusion  
in infective endocarditis, 165-166
- Adult Treatment Panel III (ATP III)  
report on cholesterol management, **393-398**.  
See also *National Cholesterol Education Program (NCEP), guidelines for cholesterol management, ATP III report on*.
- Age  
as factor in extracorporeal mechanical circulatory support devices, 29  
as factor in surgical treatment for infective endocarditis, 248  
of heart  
as factor in coronary calcium use, 543-544
- Alcohol  
and health  
history of, 450  
biology of, 452-453

- Alcohol (*continued*)  
in vascular biology, 453-454  
moderate consumption of  
in cardiovascular disease prevention,  
449-457  
reduction of  
in hypertriglyceridemia management,  
422-423
- ALVAD. *See* Abdominal left ventricular assist device (ALVAD).
- Aneurysm(s)  
aortic  
MDCT of, 610-613
- Angiography  
in coronary arteriosclerosis and coronary artery calcium, 523-524  
MDCT  
of aorta, 610  
minimally invasive  
using CT  
clinical results of, 549-559. *See also* Computed tomography (CT), minimally invasive angiography using.  
peripheral arterial  
MDCT with, 621-623  
pulmonary  
for pulmonary embolism, 629-630
- Angiotensin-converting enzyme (ACE) inhibitors  
in cardiovascular disease prevention, 474-475
- Antibiotic(s)  
for coronary artery disease, 346-349  
for infective endocarditis in HIV-1-infected patients, 175  
for infective endocarditis in IV drug abusers, 171-174  
for prosthetic valve endocarditis, 259-260
- Anticoagulant(s)  
for prosthetic valve endocarditis, 262  
in cardiovascular disease prevention, 476  
in CardioWest TAH implantation, 110-113
- Anticoagulation  
mechanical circulatory support and, 32
- Antimicrobial agents. *See* Antibiotic(s).
- Antiplatelet agents  
in cardiovascular disease prevention, 476
- Aorta  
MDCT angiography of, 610  
MDCT of, 605-627. *See also* Multi-detector row computed tomography (MDCT).
- Aortic aneurysm  
MDCT of, 610-613
- Aortic dissection  
MDCT of, 614-618
- Aortic trauma  
MDCT of, 619-621
- Apoptosis  
in heart failure, 88-89
- Arrhythmia(s)  
extracorporeal mechanical circulatory support devices for, 31  
VAD response to, 24
- Arrow LionHeart pump  
as destination therapy, 69
- Arteriosclerosis  
coronary  
coronary calcium and, 521-528. *See also* Coronary calcium, coronary arteriosclerosis and.
- Arthralgia(s)  
in infective endocarditis, 162
- Arthritis  
in infective endocarditis, 162
- Artificial hearts. *See also* specific types, e.g., CardioWest.  
AbioCor  
patient selection for, 121-124  
CardioWest  
patient selection for, 119-121  
infections of, 267  
patient selection for, 119-125
- Atherogenesis  
diabetes and, 399-400  
inflammation in, 315-332  
clinical applications of, 317-319  
prevention of, 320-322
- Atherosclerosis  
*Chlamydia pneumoniae* and, 336-343  
animal studies of, 340-341  
historical background of, 336-337  
mechanistic studies of, 341-342  
pathologic evidence of, 338-340  
serologic evidence of, 337-338  
CMV and, 349-351  
C-reactive protein and, 328-329  
diagnosis of  
CT and MRI in, 642-650  
*Helicobacter pylori* and, 343-344

- herpes viruses and, 352
- HIV and, 352-353
- influenza virus and, 352-353
- Mycoplasma pneumoniae* and, 344-345
- pathogen burden as aggregate serologic risk factor for, 353
- periodontal disease and, 346

Atherosclerotic plaque  
coronary calcium and, 535-537

Atherosclerotic ulcer  
penetrating  
and intramural hematoma  
MDCT of, 618-619

ATP III. *See Adult Treatment Panel III (ATP III).*

Axial blood flow pumps  
advantages of, 10  
hemodynamics characteristics of, 24-25

## B

Bacteremia  
persistent  
surgical treatment for infective endocarditis for, 246  
*Staphylococcus aureus*, **219-233**. *See also Staphylococcus aureus bacteremia.*

Bacteria  
extracellular fastidious  
in infective endocarditis diagnosis, 211  
isolation of  
in infective endocarditis, **197-205**  
*Bartonella* serology  
in infective endocarditis diagnosis, 210  
*Bartonella* sp  
in infective endocarditis diagnosis, 212

B-cell hyperreactivity  
in LVAD recipients, 132-134  
therapeutic interventions for, 134-137

Bile acid sequestrants  
for lipid disorders, 369

Biomaterial(s)  
implanted  
human immunologic responses to, 127-129

Bleeding  
mechanical circulatory support and, 32

$\beta$ -Blocker therapy  
in cardiovascular disease prevention, 475-476

Blood cultures  
in infective endocarditis diagnosis, 199-203

Blood flow pumps  
axial  
advantages of, 10

Blood pressure  
exercise training effects on, 441

Body weight  
composition of, 440-441

## C

Calcium  
coronary  
coronary artery disease related to, **521-534**

Calcium homeostasis  
LVAD effects on, 90-91

Carbohydrate(s)  
reduction of  
in hypertriglyceridemia management, 422

Carbohydrate metabolism  
exercise training effects on, 440

Cardiac rehabilitation  
as secondary prevention, 444  
compliance in, 442-444  
cost effectiveness of, 444  
effects on cardiovascular outcomes, **435-448**  
participation in, 442-444

Cardiac valvular disease  
*Staphylococcus aureus* bacteremia due to, 221

Cardiogenic shock  
acute  
management of, **43-50**  
devices in, 43-45  
historical background of, 43-44  
IABP, 43-44  
VADs, 44-45  
postcardiotomy  
short-term VADs for, 78-79

Cardiomyopathy  
quantitative CT methods in, 571

Cardiopulmonary bypass  
historical perspective of, 1-2

Cardiovascular diseases  
antihyperglycemic agents and, 401-402  
cardiac rehabilitation effects on, **435-448**.  
*See also Cardiac rehabilitation.*  
C-reactive protein and, **315-325**  
C-reactive protein as predictor of, **327-331**  
epidemiology of, 450-452

Cardiovascular diseases (*continued*)

exercise effects on, **435-448**. *See also*

*Exercise training.*

hyperglycemia and, 401

in diabetics, **399-413**. *See also Diabetes.*

inflammation and, **315-325**

obesity and, 424-425

prevention of

in daily practice, **471-482**

ACE inhibitors, 474-475

anticoagulants, 476

antiplatelet agents, 476

$\beta$ -blocker therapy, 475-476

cigarette smoking cessation, 471-472

hormone replacement therapy, 476-477

hyperlipidemia management, 472-473

hypertension management, 473-474

physical activity, 475

weight reduction, 475

lack of implementation in, 477-478

moderate alcohol and wine

consumption in, **449-457**. *See also Alcohol; Wine.*

primary and secondary

evidence supporting, 471-477

programs for

strategies in development of, 478-479

## CardioWest TAH, 8, 119-121

described, 120

historical background of, 106-107, 119

implantation of, 110

anticoagulation therapy and

monitoring during, 110-113

guidelines for, 110

survival following, 113-115

techniques for, 110

indications for, 110

indications for, 120-121

studies of, 121

ventricles and console of, 107-109

## Cellular restoration, 91-92

## Centrifugal pumps

hemodynamics characteristics of, 25

## Cerebral vascular accident

in infective endocarditis, 164-165

## Chest radiography

for pulmonary embolism, 629

in infective endocarditis diagnosis, 192

CHF. *See Congestive heart failure (CHF).**Chlamydia pneumoniae*

atherosclerosis due to, 336-343. *See also*

*Atherosclerosis, Chlamydia pneumoniae and.*

## Cholesterol

isolated low HDL

management of, 382-383

LDL, **363-375**. *See also Low-density lipoprotein cholesterol (LDL-C).*

national education treatment for. *See National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP).*

guidelines of, 363-365

NCEP guidelines for

ATP III report on, **393-398**. *See also National Cholesterol Education Program (NCEP), guidelines for cholesterol management, ATP III report on.*

## Cholesterol absorption inhibitors

for lipid disorders, 370-371

## Chronic wasting disease

in infective endocarditis, 162

## Cigarette smoking

cessation of

in cardiovascular disease prevention, 471-472

## Circulatory failure

right-sided

mechanical circulatory support and, 32

VADs for, 53-54

## Circulatory support

mechanical

early history of, 1-2

CMV. *See Cytomegalovirus (CMV).*

## Community preparation

in outpatient management of patients on long-term assist devices, 101

## Competency

in outpatient management of patients on long-term assist devices, 99

## Compliance

in cardiac rehabilitation, 442-444

## Computed tomography (CT)

cardiac, **491-513, 561-585**

advantages of, 505-506

complementary results of, **637-653**

evolution of, 492-505

first-phase of, 493-500

fourth phase of, 501-505

- future possibilities for, 506-508
- limitations of, 505-506
- of coronary calcification in ischemic heart disease, 565
- of ischemic left ventricular myocardium, 565-570
- of myocardial infarction, 565-570
- quantitative methods, 570-582
- second phase of, 500-501
- third phase of, 501
- coronary calcium scanning with
  - clinical use of, **535-547**. *See also Coronary calcium scanning, with CT.*
- described, 491
- diagnosis of, 192-193
- fast
  - in myocardial vasculature imaging, **587-604**. *See also Myocardial vasculature, CT in imaging of, fast.*
- for deep venous thrombosis, 631-634
- for pulmonary embolism, 631-634
- historical background of, 491
- image reconstruction in, 515-518
  - definitions associated with, 515
  - historical background of, 515
  - technique of, 515-518
- in atherosclerosis, 642-650
- in venous thromboembolic disease, **629-636**.  
*See also Venous thromboembolic disease, CT in.*
- minimally invasive angiography using
  - clinical applications of
  - results of, 553-555
  - clinical results of, **549-559**
  - methods in, 550-551
  - results of, 551-553
  - visualization of non-calcified plaque on, 555-556
- of coronary arteries
  - complementary results of, **637-653**
- physics and dosimetry in, **515-520**
- quantitative methods
  - in cardiac assessment, 570-582. *See also specific disorder, e.g., Cardiomyopathy.*
- radiation dose for, 518-519
- three-dimensional microscopic
  - in myocardial vasculature imaging, **587-604**. *See also Myocardial vasculature, CT in imaging of, three-dimensional microscopic.*
- Congestive heart failure (CHF)
  - described, 87
- infective endocarditis and, 273-274
  - surgical treatment for, 237-242
- mortality of, 1
- prevalence of, 1, 57
- Continuous blood flow
  - technology in
  - advances in, 9-10
- Contrast venography
  - for deep venous thrombosis, 630
- Coronary arteriosclerosis
  - coronary artery calcium and, 521-528. *See also Coronary artery calcium, coronary arteriosclerosis and.*
- Coronary artery disease. *See also Atherosclerosis.*
  - chronic infection and, **333-362**
  - chronic inflammation as predictor of, 333-336
  - coronary calcium related to, **521-534**. *See also Coronary calcium, coronary artery disease related to.*
  - diagnosis of
    - CT and MRI in, 638-642
  - extracorporeal mechanical circulatory support devices for, 31
  - pathogen burden as aggregate serologic risk factor for, 353
  - treatment of
    - antimicrobial agents in, 346-349
  - VAD response to, 24
- Coronary artery stenosis
  - epicardial
    - microvascular dysfunction in presence of, 591-592
- Coronary calcification
  - in ischemic heart disease
  - detection of
  - CT in, 565
- Coronary calcium
  - atherosclerotic plaque and, 535-537
  - coronary arteriosclerosis and, 521-522
  - coronary angiography in, 523-524
  - exercise ECG in, 527
  - extent of disease, 522-527
  - histopathology of, 523
  - intracoronary ultrasonography in, 524-527
  - myocardial perfusion measurements in, 527
  - natural history of, 527-528
  - severity factors, 522-527
  - coronary artery disease related to, **521-534**
  - heart age and

Coronary calcium (*continued*)

- factors related to, 543-544
- high-risk coronary plaques and, 528-529
- long-term risk as factor in use of, 543-544
- progression of, 529-530
- with CT
  - clinical outcomes of, 539-541
  - in asymptomatic patients, 541-542

## Coronary calcium scanning

- with CT
  - clinical use of, **535-547**
  - electron beam tomography methods in, 536-537
  - multi-detector methods in, 537-538
    - vs. electron beam tomography, 538
  - radiation exposure in, 539

## Coronary heart disease

- mortality due to, 459
- prevention of
  - barriers to, **459-470**
  - cardiologist-related, 464-467
  - patient-related, 460-461
  - physician intervention-related, 461-464
- risk factors for, 364

## Coronary plaque

- high-risk
  - coronary artery calcium and, 528-529

*Coxiella burnetii* morphology

- in infective endocarditis diagnosis, 207

*Coxiella burnetii* serology

- in infective endocarditis diagnosis, 209

## C-reactive protein

- as predictor of cardiovascular disease, **327-331**
- atherosclerosis due to, 328-329
- cardiovascular disease and, **315-325**
- lowering of
  - methods for, 330
- measurements of
  - guidelines for, 329-330
- plaque instability due to, 328-329

CT. *See* Computed tomography (CT).

## Cyclophosphamide

- for B-cell hyperreactivity, 134-137

## Cytomegalovirus (CMV)

- atherosclerosis and, 349-351

**D**

## D-dimer tests

- for deep venous thrombosis, 630
- for pulmonary embolism, 630

## Deep venous thrombosis

- diagnostic tests for, 630-633
  - contrast venography, 630
  - CT, 631-634
  - D-dimer tests, 630
  - MRI, 630
  - venous ultrasonography, 630

## Destination therapy

- devices as, **67-73**

## Device(s)

- as destination therapy, **67-73**.  
*See also* specific device, e.g., *Pulsatile LVADs*,
  - clinical trials of, 71-72
  - patient selection in, 70-71

## Diabetes

- atherogenesis and, 399-400
- cardiovascular disease in patients with, **399-413**
- hypertension in patients with, 406-407
- LDL-C in
  - statin trials for, 403-404
  - with hypertriglyceridemia, 404-406
- lipid disorders in patients with, 403-406
- prevention of
  - studies of, 403
- procoagulant state in, 408-409
- renal disease in patients with, 408

## Diet(s)

- vascular outcomes of, 416-419

## Dietary fiber

- in obesity management, 421

## Dietary modification

- in obesity management, **415-433**. *See also* *Obesity, treatment of, dietary modification in*.

## Displacement pumps

- hemodynamics characteristics of, 25

## Distal microembolism

- microvascular dysfunction in response to, 592-594

## Dosimetry

- in CT, **515-520**

## Drug(s)

- in outpatient management of patients on long-term assist devices, 99

## Drug abuse

- as factor in surgical treatment for infective endocarditis, 248-249

## Drug abusers

## IV

infective endocarditis in, **167-176**. *See also*  
*Infective endocarditis, in IV drug abusers.*

**E**

EBCT. *See Electron beam computed tomography (EBCT).*

ECG. *See Electrocardiography (ECG).*

## Echocardiography

## abnormal findings on

in infective endocarditis, 163-164

in infective endocarditis diagnosis, 185-192

cost effectiveness of, 191-192

described, 185-186

findings of, 188-191

technique of, 186-187

in *Staphylococcus aureus* bacteremia diagnosis, 223-225

## transesophageal

for pulmonary embolism, 630

ECMO. *See Extracorporeal membrane oxygenation (ECMO).*

## Electrical synchrony

importance of, 145-146

## Electrocardiography (ECG)

## exercise

in coronary arteriosclerosis and coronary artery calcium, 527

Electron beam computed tomography (EBCT), 549-556

in coronary calcium scanning, 536-537

vs. multi-detector CT methods, 538

minimally invasive angiography using

clinical applications of

results of, 553-555

methods in, 550

results of, 551

## Electron microscopy

in infective endocarditis diagnosis, 208-209

## Embolism

pulmonary. *See Pulmonary embolism.*

## Embolus(i)

## pulmonary

## septic

in infective endocarditis, 164

## Emergency issues

in outpatient management of patients on  
long-term assist devices, 100

## Endocarditis

## fungal

surgical treatment for, 246-247

## infective

global understanding of, **147-158**. *See also*  
*Infective endocarditis, global*  
*understanding of.*

## left-sided native valve

treatment of, 227

prosthetic valve, 163. *See Prosthetic valve*  
*endocarditis.*

surgical treatment of, 247

## right-sided native valve endocarditis

treatment of, 227

*Staphylococcus aureus*, **219-233**. *See also*  
*Staphylococcus aureus endocarditis.*

## Endothelial dysfunction

uncoupling of nitric oxide synthases and,  
294-295

## Endothelial function

exercise training effects on, 441

myocardial perfusion measurement in,  
590-591

## Endothelial nitric oxide synthase (eNOS)

endogenous antagonists of, 297

expression of, 295-297

## Endothelium

in vascular tone modulation, 289-290

## End-stage heart failure

future directions in, **143-147**

eNOS. *See Endothelial nitric oxide synthase (eNOS).*

## Epicardial coronary artery stenosis

microvascular dysfunction in presence of,  
591-592

Exercise. *See Exercise training.*

## Exercise ECG

in coronary arteriosclerosis and coronary  
artery calcium, 527

## Exercise tolerance

exercise training and, 438-439

## Exercise training

blood pressure effects of, 441

body weight and composition effects of,  
440-441

carbohydrate metabolism effects of, 440

cardiovascular morbidity effects of, 437-438

cardiovascular mortality effects of, 436-437



Exercise training (*continued*)

- clinical outcomes of
  - intermediate, 439-440
  - primary, 436-439
- effects on cardiovascular outcomes, **435-448**
- endothelial function effects of, 441
- exercise tolerance due to, 438-439
- physical functioning effects of, 442
- plasma lipid values and, 439-440
- quality-of-life outcomes related to, 441-442
- strength due to, 439

## Extracardiac invasive infections

- surgical treatment for infective endocarditis and, 248

## Extracellular fastidious bacteria

- in infective endocarditis diagnosis, 211

## Extracellular matricial alterations

- heart failure progression caused by, 89

## Extracorporeal centrifugal pumps, 35

Extracorporeal mechanical circulatory support devices, **29-42**. *See also Mechanical circulatory support (MCS).*

- Abiomed BVS 5000, 38-40
- adverse events associated with, 32
- age as factor in, 29
- ECMO, 33-35
- extracorporeal centrifugal pumps, 35
- for arrhythmias, 31
- for coronary artery disease, 31
- for valvular heart disease, 30-31
- intracardiac shunts, 31
- patient selection for, 29
- Tandem Heart pVAD, 35-36
- temporary
  - considerations related to, 30-33
- Thoratec Ventricular Assist System, 36-38
- timing of, 29-30
- types of, 33-40

## Extracorporeal membrane oxygenation (ECMO), 33-35

---

**F**

## Fiber

- dietary
- in obesity management, 421

## Fibrate(s)

- for diabetic dyslipidemia, 405-406
- for lipid disorders, 368-369

## Fish oil

- in hypertriglyceridemia management, 423

## Fluid dynamic-rotary pumps

- hemodynamic characteristics of, 24

## Fungal endocarditis

- surgical treatment for, 246-247

## Fungus(i)

- isolation of
- in infective endocarditis, **197-205**

---

**H**HDL-C. *See High-density lipoprotein cholesterol (HDL-C).*

## Heart

- age of
  - as factor in coronary calcium use, 543-544
- anatomy of, 561-565
- artificial. *See Artificial hearts.*
- infections of, 267
- assessment of
  - CT in, **561-585**. *See also Computed tomography (CT), cardiac.*
- CT of
  - complementary results of, **637-653**
- defects of
  - congenital
    - VAD response to, 24
- diseased
  - near normal functional status of
  - reasons for, 145
  - recovering function by
  - incapability of, 143-144
- infective endocarditis effects on, 148-149
- MRI of
  - complementary results of, **637-653**
- total artificial
  - historical perspective of, **1-13**. *See also Total artificial hearts (TAHs).*

## Heart disease

- valvular
  - extracorporeal mechanical circulatory support devices for, 30-31

## Heart failure

- apoptosis in
  - heart failure progression caused by, 88-89
- congestive. *See Congestive heart failure (CHF).*
- end-stage
  - future directions in, **143-147**
- mortality resulting from
  - reasons for, 146
- physiology of, 17-18
- progression of



- left ventricular remodeling and, 87-89
  - apoptosis in heart failure and, 88-89
  - cardiac myocyte loss and, 88
  - cellular component alterations and, 88
  - extracellular matrix alterations and, 89
  - subcellular component alterations and, 88
- reverse modeling in
  - feasibility of, 90-92
- types of
  - assist devices for, 144-145
- unexplained
  - in infective endocarditis, 162
- HeartMate, 5-6, 57-58
  - as destination therapy, 68 *Helicobacter pylori*
  - atherosclerosis due to, 343-344
- Hematoma(s)
  - atherosclerotic
    - penetrating
      - and intramural hematoma
        - MDCT of, 618-619
  - intramural
    - MDCT of, 618-619
- Herpes viruses
  - atherosclerosis and, 352
- High-density lipoprotein cholesterol (HDL-C)
  - isolated low
    - management of, 382-383
- HIV. *See Human immunodeficiency virus (HIV).*
- Home documentation
  - in outpatient management of patients on
    - long-term assist devices, 101
- Home evaluation
  - in outpatient management of patients on
    - long-term assist devices, 101
- Hormone replacement therapy (HRT)
  - in cardiovascular disease prevention, 476-477
- Human immunodeficiency virus (HIV)
  - atherosclerosis and, 352
- Human immunodeficiency virus (HIV)-type 1-infected patients
  - infective endocarditis in, 176-179. *See also Infective endocarditis, in HIV-1-infected patients.*
- Hyperglycemia, 401-403
  - cardiovascular events due to, 401
  - postprandial, 403

- Hyperlipidemia
  - after solid organ transplantation
    - management of, 386-387
  - renal diseases-related
    - management of, 384-386
  - treatment of
    - in cardiovascular disease prevention, 472-473
- Hypertension
  - in diabetics, 406-407
  - treatment of
    - in cardiovascular disease prevention, 473-474
- Hypertriglyceridemia
  - and LDL-C
    - in diabetics, 404-406
  - differential diagnosis of, 378-381
  - treatment of, 377-382
    - alcohol reduction in, 422-423
    - dietary carbohydrates limits in, 422
    - drugs in, 381-382
    - fish oil in, 423
    - nonpharmacologic approaches in, 381
    - weight loss in, 422-423
  - triglyceride metabolism in, 377-378

---

## I

- IABP. *See Intra-aortic-balloon-pump (IABP).*
- Image reconstruction
  - in CT, 515-518
- Immunohistologic testing
  - in infective endocarditis diagnosis, 208
- Implantable ventricular assist device (IVAD)
  - Thoratec, 58
- Infarction(s)
  - myocardial
    - short-term VADs for, 79
- Infection(s)
  - chronic
    - coronary artery disease due to, 333-362
  - in outpatient management of patients on
    - long-term assist devices, 99
  - mechanical circulatory support and, 32-33
  - of intracardiac devices, 253-271. *See also specific infection and Intracardiac devices, infections of.*
  - uncontrolled
    - infective endocarditis and, 277-278

## Infectious endocarditis

- in *Staphylococcus aureus* bacteremia
- identification of, 223
- Staphylococcus aureus*, 222-223

## Infective endocarditis

- acute peripheral vascular occlusion in, 165-166
- arthralgias in, 162
- arthritis in, 162
- cardiac risk factors associated with, 148-149
- cerebral vascular accident in, 164-165
- chronic wasting disease in, 162
- clinical presentation of, **159-166**
- clinical response to patients with evaluation of, 279
- complications of, **273-282**
  - congestive heart failure, 273-274
  - metastatic abscesses, 278
  - paravalvular abscesses, 274-275
  - renal, 279
  - stroke, 275-277
  - uncontrolled infection, 277-278
- current understanding of, 148
- dental effects of, 149
- diagnosis of, 150-151, **197-205**
  - bacteria isolation in, **197-205**
  - best practices in, 199-202
  - chest radiography in, 192
  - CT in, 192-193
  - difficult-to-culture pathogens in identification of, **207-217**
    - Bartonella* sp. in, 212
    - Bartonella* sp. serology in, 210
    - Coxiella burnetii* serology in, 209
    - culture methods in, 210-213
    - extracellular fastidious bacteria in, 211
    - morphologic methods in, 207-209
    - PCR amplification in, 213
    - Q fever in, 211-212
    - serologic testing in, 209-210
    - Warthin-Starry technique in, 208
- echocardiography in, 185-192. *See also Echocardiography, in infective endocarditis diagnosis.*
- fungi isolation in, **197-205**
- imaging techniques in, **185-195**
- microbiologic findings in, 198-199
- MRI in, 192-193
- nuclear medicine imaging in, 193
- optimal antiseptic skin preparation in, 199
- optimal choice of blood culture media in, 201-202

- optimal length of incubation for blood cultures in, 202

- optimal number of blood cultures in, 200-201

- optimal timing of blood cultures in, 199-200

- optimal volume of blood for culture in, 201
- special considerations in, 203

## echocardiogram in

- abnormal, 163-164

## epidemiology of, 148

## fever in, 159-161

## future directions in, 151-154

global understanding of, **147-158**

- controlled clinical trials in, 154-156

- limitations in, 151

## heart failure in, 162

## host factors associated with, 148-150

## in HIV-1-infected patients

- causes of, 176

- clinical characteristics of, 176

- incidence of, 175-176

- not related to IV drug abuse, 176-178

- causes of, 176-177

- clinical characteristics of, 176-177

- incidence of, 176

- prognosis of, 178

- treatment of, 178

## prognosis of, 176

## treatment of

- antibiotic, 176

- surgical, 176

in IV drug abusers, **167-176**

- causes of, 168

- described, 167

- diagnosis of, 169-171

- prognosis of, 171

## treatment of

- antibiotic, 171-174

- surgical, 174-175

- valve involvement in, 168-169

## intensive medical care and, 149-150

## microorganisms and, 150

## pathophysiology of, 197-198

## periannular extension of infection in

- treatment of

- surgical, 242-245

## pericarditis in, 162-163

## prognosis of, 166

## prosthetic valve endocarditis in, 163

## recurrent, 279-280

## regional variation in, 148

## renal failure in, 165

- sepsis in, 161-162
  - septic pulmonary emboli in, 164
  - signs and symptoms of, 159-166
  - study of
    - controlled clinical trials in, 154-156
  - treatment of, 151
  - complications of, 280-281
  - surgical
    - age as factor in, 248
    - drug abuse and, 248-249
    - extracardiac invasive infections due to, 248
  - indications for, **235-251**
    - congestive heart failure, 237-242
    - difficult-to-treat organisms, 247
    - fungal endocarditis, 246-247
    - persistent bacteremia, 246
    - prosthetic valve endocarditis, 247
    - systemic embolization risk, 245-246
    - unstable prosthesis, 247
    - valve obstruction, 246
    - vegetations, 245-246
  - neurologic complications due to, 248
  - timing of, 236
- Inflammation
- and vascular remodeling, 454-455
  - cardiovascular disease and, **315-325**
  - chronic
    - as coronary artery disease predictor, 333-336
    - causes of, 336
  - in atherogenesis, 315-332. *See also Atherogenesis, inflammation in.*
- Influenza virus
- atherosclerosis and, 352-353
- Insulin
- for hyperglycemia
  - cardiovascular effects of, 402
- Insulin resistance
- metabolic syndrome and, 400-401
- Intermediate facility
- in outpatient management of patients on long-term assist devices, 98
- International Collaboration on Endocarditis Investigation, **147-158**. *See also Infective endocarditis, global understanding of.*
- characteristics of, 153
  - cohort study, 153-154
  - database merger in, 152-153
  - working group in, 151-152
- Intra-aortic-balloon-pump (IABP)
- for acute cardiogenic shock, 43-44
- Intracardiac devices
- artificial hearts
  - infections of, 267
  - implantable electrophysiologic
  - infections of, 262-267
    - anatomy of, 262-263
    - classification of, 262-264
    - clinical presentation of, 265-266
    - epidemiology of, 264
    - management of, 266-267
    - microbiology of, 264-265
    - pathogenesis of, 262-264
    - risk factors for, 264
  - infections of, **253-271**
  - left ventricular assist devices
  - infections of, 267
- Intracardiac masses
- quantitative CT methods in, 574-575
- Intracardiac shunts, 31
- Intramural hematoma
- MDCT of, 618-619
- Intravenous drug abusers
- infective endocarditis in, **167-176**. *See also Infective endocarditis, in IV drug abusers.*
- Ischemic heart disease
- coronary calcification in
  - detection of
  - CT in, 565
- Ischemic left ventricular myocardium
- assessment of
  - CT in, 565-570
- Isolated low HDL-C
- management of, 382-383
- IVAD. *See Implantable ventricular assist device (IVAD).*
- 
- J**
- 
- Jarvik 2000
- as destination therapy, 69-70
- Jarvik-7, 8, 9
- 
- K**
- 
- Kidney(s)
- infective endocarditis effects on, 165, 279

**L**

LDL-C. *See* Low-density lipoprotein cholesterol (LDL-C).

Left ventricular assist devices (LVADs), 2-5

effect on calcium homeostasis, 90-91

effect on mechanical function of heart, 90

effect on neurohormone levels, 91

implantation of

aberrant immune activation with  
systemic consequences of, 129-132

long-term

historical background of, 51-52

indications for, 51-56

pulsatile

as destination therapy, 67-69

pulsatile implantable, 57-65. *See also* Pulsatile  
LVADs, implantable.

recipients of

B-cell hyperreactivity in, 132-134

T-cell defects in

clinical consequences of, 132-134

Left ventricular myocardium

ischemic

assessment of

CT in, 565-570

Left-sided native valve endocarditis

treatment of, 227

Lifestyle change

therapeutic

in obesity management, 416

LionHeart LVAD, 58-60

Lipid disorders

in diabetics, 403-406

treatment of, 368-371.

*See also* specific disorder, e.g.,

*Hypertriglyceridemia.*

bile acid sequestrants in, 369

combination drug therapy in, 370

fibrates in, 368-369

hypertriglyceridemia, 377-382

nicotinic acid in, 369

selective cholesterol absorption inhibitors  
in, 370-371

statins in, 368

Lipoprotein(a)

elevated

management of, 383-384

Long-term assist devices

outpatient management of, 97-103

activities in, 102

assessment of need for intermediate facility  
in, 98

community preparation in, 101

competency in, 99

complications in, 102-103

discharge preparation, 98-100

drugs in, 99

emergency issues in, 100

equipment in, 100

follow-up care, 102

home documentation in, 101

home evaluation in, 101

infection and, 99

nutrition in, 98

practitioner's role in, 97-98

reconditioning in, 98

support persons in, 99-100

transportation issues in, 100

travel issues in, 100

work issues in, 101-102

wound management in, 99

Low-density lipoprotein cholesterol (LDL-C)

goals for, 363-375

target levels, 366-368

hypertriglyceridemia and

in diabetics, 404-406

in diabetics

statin trials for, 403-404

treatment for

method of, 367-368

LVADs. *See* Left ventricular assist devices  
(LVADs).

LVAS. *See* Novacor left ventricular assist system  
(LVAS).

**M**

Magnetic resonance imaging (MRI)

in atherosclerosis, 642-650

in deep venous thrombosis, 630

in infective endocarditis diagnosis, 192-193

of heart and coronary arteries

complementary results of, 637-653

of pulmonary embolism, 630

MCS. *See* Mechanical circulatory support (MCS).

MDCT. *See* Multi-detector row computed  
tomography (MDCT).

Mechanical circulatory support (MCS), 29-42.

*See also* Extracorporeal mechanical circulatory  
support devices.

adverse events associated with, 32

- anticoagulation due to, 32
- bleeding due to, 32
- device selection in, 30
- early history of, 1-2
- infection due to, 32-33
- right-sided circulatory failure due to, 32
- thromboembolism due to, 32
- weaning patients from
  - considerations in, 33
- Metabolic syndrome
  - dietary modification in improving, 421-422
  - insulin resistance and, 400-401
  - obesity and, 401
- Metastatic abscess
  - infective endocarditis and, 278
- Metformin
  - for hyperglycemia
  - cardiovascular effects of, 401-402
- Methicillin
  - resistance to
    - Staphylococcus aureus* bacteremia effects of, 222
- Microembolism
  - distal
    - microvascular dysfunction in response to, 592-594
- Micro-Med-DeBakey VAD, 69
- Microorganism(s)
  - infective endocarditis due to, 150
- Microvascular dysfunction
  - coronary
    - in response to distal microembolism, 592-594
  - in presence of epicardial coronary artery stenosis, 591-592
- Microvascular function
  - changes during vessel growth, 590
- Molecular restoration, 91-92
- Monocyte-T-cell interactions
  - on LVAD surface result in aberrant T-cell activation, 129
- MRI. *See Magnetic resonance imaging (MRI).*
- Multi-detector row computed tomography (MDCT)
  - in coronary calcium scanning, 537-538
  - vs. electron beam tomography, 538
  - of aorta, **605-627**
    - techniques in, 605-607
    - of aortic aneurysm, 610-613
    - of aortic dissection, 614-618
    - of aortic trauma, 619-621
    - of penetrating atherosclerotic ulcer and intramural hematoma, 618-619
    - of peripheral arteries, **605-627**
      - techniques in, 605-607
    - peripheral arterial angiography and, 621-623
- Multi-detector row computed tomography (MDCT) angiography
  - of aorta, 610
- Multi-detector row computed tomography (MDCT) angiography post-processing, 607-610
- Multi-detector spiral computed tomography, 549-556
  - minimally invasive angiography using
    - clinical applications of
      - results of, 553-555
    - methods in, 550-551
    - results of, 551-553
- Mycoplasma pneumoniae*
  - atherosclerosis due to, 344-345
- Myocardial blood flow
  - relationship to blood volume, 589-590
- Myocardial blood volume
  - relationship to blood flow, 589-590
- Myocardial dysfunction
  - alteration in contractile function
    - molecular basis of, 89-90
  - pathogenesis of, **87-95**
- Myocardial infarction
  - assessment of
    - CT in, 565-570
  - short-term VADs for, 79
- Myocardial perfusion measurements
  - applications of, 590-594
  - in coronary arteriosclerosis and coronary artery calcium, 527
- Myocardial recovery
  - after long-term VAD use, 79-84. *See also Ventricular assist devices (VADs), long-term.*
  - VADs in, **75-85**. *See also Ventricular assist devices (VADs).*
    - rationale for, 75-76
    - short-term, 76-79

## Myocardial vasculature

- CT in imaging of
  - fast, **587-604**
  - future directions in, 601-602
  - three-dimensional microscopic, **587-604**
  - cryogenic, 599-601
- function of
  - modeling indices of
  - indicator dilution principles in, 588-589

## Myocarditis

- acute fulminant
- short-term VADs for, 79

## Myocardium

- ischemic left ventricular myocardium
- assessment of
- CT in, 565-570

## Myocyte(s)

- cardiac
- loss of
  - heart failure progression caused by, 88

---

**N**

## National Cholesterol Education Program (NCEP)

- guidelines for cholesterol management
  - ATP III report on, **393-398**
  - described, 393-394
  - new features of, 394-397
  - 9 steps in, 397-398

## National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP)

- LDL-C goals of, 363-364
- therapeutic lifestyle change diet of, 364-365

## National Health and Nutrition Examination Survey III (NHANES III), 364-365

NCEP. *See National Cholesterol Education Program (NCEP).*

## Nephrotic syndrome

- management of, 384-385

## Neurohormone levels

- LVAD effects on, 91

## Neurologic complications

- surgical treatment for infective endocarditis and, 248

## Niacin

- for diabetic dyslipidemia, 406

## Nicotinic acid

- for lipid disorders, 369

## Nitric acid production

- endothelial control of, **298-302**

## Nitric oxide

- bioavailability in vascular diseases, 292-293
- in vascular tone regulation, 290-291
- production of
  - alteration of, 292-293
- roles of, 290-291
- vasodilation by
  - method of, 291

## Nitric oxide synthases

- endothelial
  - endogenous antagonists of, 297
  - expression of, 295-297
- uncoupling of
  - endothelial dysfunction due to, 294-295

## Novacor, 57-58

## Novacor left ventricular assist system (LVAS), 4-6

## Novacor pump

- as destination therapy, 68-69

## Nuclear medicine imaging

- in infective endocarditis diagnosis, 193

## Nutrition

- in outpatient management of patients on long-term assist devices, 98

---

**O**

## Obesity

- assessment of patient with, 424
- cardiovascular disease and, 424-425
- defined, 424, 440
- metabolic syndrome and, 401
- pathophysiology of, 425-426
- treatment of
  - dietary modification in, **415-433**
    - dietary fiber, 421
    - effects on lipids, 419-422
    - in improving metabolic syndrome, 421-422
    - plant sterols, 419
    - risk factor effects of, 419-422
    - Step I and II diets, 415-416
    - therapeutic lifestyle change, 416
    - trans fatty acids, 419-421
    - triglycerides levels, 422
    - vascular outcomes of, 416-419
  - goals in, 427-429
  - modalities in, 427-429
  - weight loss in, 422-423

**P**

- Paravalvular abscess  
infective endocarditis and, 274-275
- PCR. *See* Polymerase chain reaction (PCR).
- Penetrating atherosclerotic ulcer  
and intramural hematoma  
MDCT of, 618-619
- Pericardial disease  
quantitative CT methods in, 579-582
- Pericarditis  
in infective endocarditis, 162-163
- Periodontal disease  
atherosclerosis and, 346
- Peripheral arterial angiography  
MDCT with, 621-623
- Peripheral arteries  
MDCT of, **605-627**. *See also* Multi-detector  
row computed tomography (MDCT), of  
peripheral arteries.
- Physical activity  
in cardiovascular disease prevention, 475
- Physical functioning  
exercise training effects on, 442
- Physics  
in CT, **515-520**
- Plant sterols  
in obesity management, 419
- Plaque  
atherosclerotic  
coronary calcium and, 535-537  
coronary  
high-risk  
coronary artery calcium and, 528-529  
non-calcified  
visualization of  
on minimally invasive angiography using  
CT, 555-556
- Plaque instability  
C-reactive protein and, 328-329
- Plaque rupture  
altered extracellular matrix breakdown and  
synthesis in, 305-307  
determinants of, 303-304  
in animal models, 307-209  
thrombosis after, 307-308  
triggers for, 307  
mechanism of, 305-307  
pathophysiology of, **303-314**  
plaque composition and, 304-305  
role of, 303  
stenosis severity and, 303-304
- Plaque stabilization, **303-314**  
in animal models, 309
- Plasma lipid values  
exercise training effects on, 439-440
- Plasmapheresis  
for B-cell hyperreactivity, 134-135
- Polymerase chain reaction (PCR) amplification  
in infective endocarditis diagnosis, 213
- Postcardiotomy shock, 45-46  
postcardiogenic  
short-term VADs for, 78-79
- Precardiotomy shock, 46-48
- Prosthesis(es)  
unstable  
surgical treatment for infective endocarditis  
for, 247
- Prosthetic implants  
*Staphylococcus aureus* bacteremia due to,  
221
- Prosthetic valve endocarditis, 253-262  
clinical manifestations of, 257  
diagnosis of, 257-259  
in infective endocarditis, 163  
laboratory manifestations of, 257  
microbiology of, 255-256  
pathogenesis of, 253-255  
pathology of, 256  
prevalence of, 253  
risk factors for, 253  
treatment of, 227-228  
anticoagulants in, 262  
antimicrobial, 259-260  
surgical, 247, 260-262
- Protein  
C-reactive  
cardiovascular disease and, **315-325**.  
*See also* C-reactive protein.
- Pulmonary angiography  
for pulmonary embolism, 629-630
- Pulmonary emboli  
septic  
in infective endocarditis, 164
- Pulmonary embolism  
diagnostic algorithm for, 634-635



**Pulmonary embolism (continued)**

- diagnostic tests for, 629-630
  - chest radiography, 629
  - CT, 631-634
  - D-dimer tests, 630
  - MRI, 630
  - pulmonary angiography, 629-630
  - transesophageal echocardiography, 630
  - ventilation/perfusion lung scintigraphy, 629

**Pulsatile LVADs**

- as destination therapy, 67-69
- development of, 2-6
- implantable, **57-65**
  - complications of, 62-64
  - family training for, 61
  - follow-up protocol, 61
  - HeartMate, 57-58
  - LionHeart, 58-60
  - medications for, 61
  - methods of, 60
  - Novacor, 57-58
  - out-of-hospital program of, 60-61
  - patient selection for, 60
  - patient training for, 61
  - results of, 61-62
  - Thoratec IVAD System, 58

---

**Q**

- Q fever
  - in infective endocarditis diagnosis, 211-212

**Quality-of-life**

- exercise training effects on, 441-442

---

**R**

- Radiation dose
  - in CT, 518-519
- Radiation exposure
  - in coronary calcium scanning, 539
- Radiography
  - chest
    - for pulmonary embolism, 629
    - in infective endocarditis diagnosis, 192
- Reactive oxygen species
  - in vascular cells
    - source of, 293-294
  - in vascular diseases
    - xanthine oxidase as source of, 295
- Rehabilitation
  - cardiac
    - effects on cardiovascular outcomes, **435-448**. *See also Cardiac rehabilitation.*

**Renal diseases**

- chronic
  - dialysis and management of, 385-386
- hyperlipidemia and management of, 384-386
- in diabetics, 408

**Renal failure**

- in infective endocarditis, 165

**Right ventricular disease**

- quantitative CT methods in, 571-574

**Right-sided circulatory failure**

- mechanical circulatory support and, 32

**Right-sided native valve endocarditis**

- treatment of, 227

**Rotary pumps**

- as destination therapy, 69-70

---

**S****Scintigraphy**

- ventilation/perfusion lung
  - for pulmonary embolism, 629

**Sepsis**

- in infective endocarditis, 161-162

**Septic pulmonary emboli**

- in infective endocarditis, 164

**Shock**

- cardiogenic
  - acute
    - management of, **43-50**. *See also Cardiogenic shock, acute, management of.*
  - postcardiotomy
    - short-term VADs for, 78-79
  - postcardiotomy, 45-46
  - precadiotomy, 46-48

**Shunt(s)**

- intracardiac, 31
- valve prosthesis/intracardiac
  - long-term, 53

**Smoking**

- cigarette
  - cessation of
    - in cardiovascular disease prevention, 471-472

**Solid organ transplantation**

- hyperlipidemia after
  - management of, 386-387 *Staphylococcus aureus* bacteremia, **219-233**
- cardiac valvular disease and, 221

- community-acquired versus healthcare-associated, 221
  - comorbid conditions, 221-222
  - complicated versus uncomplicated
    - treatment of, 224
  - complications of, 220-223
  - diagnosis of, 223-225
  - echocardiography of, 223-225
  - epidemiology of, 219-220
  - future directions in, 228-229
  - in surgical patients, 222
  - infectious endocarditis and, 222-223
    - identification of, 223
    - valve replacement therapy for, 228
  - metastatic
    - risk factors for, 221-223
  - methicillin resistance in
    - clinical impact of, 222
  - outcome of
    - factors influencing, 222
  - prevalence of
    - increasing, 219-220
  - prosthetic implants and, 221
  - treatment of, 225-228
- Staphylococcus aureus* endocarditis, **219-233**
- antibiotic resistance to
    - rates of, 220
  - prevalence of, 220
- Statin(s)
- for LDL-C in diabetics, 403-404
  - for lipid disorders, 368
- Stenosis(es)
- coronary artery
    - epicardial
      - microvascular dysfunction in presence of, 591-592
  - severity of
    - plaque rupture due to, 303-304
- Step I and II diets
- in obesity management, 415-416
- Strength
- exercise training and, 439
- Stroke
- infective endocarditis and, 275-277
- Sulfonylureas
- for hyperglycemia
    - cardiovascular effects of, 402
- Support persons
- in outpatient management of patients on long-term assist devices, 99-100

---

**T**

- TAHs. *See* Total artificial hearts (TAHs).
- Tanden Heart pVAD, 35-36
- T-cell activation
- aberrant
    - LVAD surface result in monocyte-T-cell interactions on, 129
- T-cell defects
- in LVAD recipients, 132-134
- Teeth
- infective endocarditis effects on, 149
- Therapeutic lifestyle change
- in obesity management, 416
- Thiazolidinediones
- for hyperglycemia
    - cardiovascular effects of, 402
- Thoratec IVAD System, 58
- Thoratec Ventricular Assist System, 36-38
- Thromboembolism
- mechanical circulatory support and, 32
- Thrombosis(es)
- deep venous
    - diagnostic tests for, 630-633. *See also* Deep venous thrombosis, diagnostic tests for,
  - determinants of, 303-304
  - in acute coronary syndromes, 303
  - plaque composition and, 304-305
- Total artificial hearts (TAHs), **105-117**
- as destination therapy, 70
  - CardioWest
    - history of, 106-107
  - evolution of, 6-10
  - historical perspective of, **1-13**
  - implantation of, 110
    - anticoagulation therapy and monitoring during, 110-113
    - complications of, 113-115
    - guidelines for, 110
    - indications for, 110
    - survival following, 113-115
    - techniques for, 110
- Trans fatty acids
- in obesity management, 419-421
- Transesophageal echocardiography
- for pulmonary embolism, 630
- Transplantation
- solid organ

Transplantation (*continued*)  
hyperlipidemia after  
management of, 386-387

Transportation issues  
in outpatient management of patients on  
long-term assist devices, 100

Trauma  
aortic  
MDCT of, 619-621

Travel issues  
in outpatient management of patients on  
long-term assist devices, 100

Triglyceride levels  
dietary modification and, 422

## U

Ultrasonography  
intracoronary  
in coronary arteriosclerosis and coronary  
artery calcium, 524-527  
venous  
for deep venous thrombosis, 630

## V

VADs. *See* Ventricular assist devices (VADs).

Valve prosthesis/intracardiac shunts  
long-term, 53

Valvular heart disease  
extracorporeal mechanical circulatory support  
devices for, 30-31  
quantitative CT methods in, 575-579

Vancomycin  
for infective endocarditis  
complications of, 280-281

Vascular cells  
reactive oxygen species in  
source of, 293-294

Vascular diseases  
nitric oxide bioavailability in, 292-293  
reactive oxygen species in  
xanthine oxidase as source of, 295

Vascular tone  
endothelium as modulator of, 289-290  
nitric oxide in regulation of, 290-291

Vasodilation  
nitric oxide and, 291

Vasomotion  
endothelial control of, 298-302

Vegetation(s)  
surgical treatment for infective endocarditis  
for, 245-246

Venography  
contrast  
for deep venous thrombosis, 630

Venous thromboembolic disease  
CT in, 629-636. *See also* Deep venous  
thrombosis, diagnostic tests for; Pulmonary  
embolism.

Venous ultrasonography  
for deep venous thrombosis, 630

Ventilation/perfusion lung scintigraphy  
for pulmonary embolism, 629

Ventricular assist devices (VADs), 75-85  
classification of, 24-25  
for acute cardiogenic shock, 44-45  
hemodynamic basis of, 24-25  
hemodynamic characteristics of  
fluid dynamic-rotary pumps, 24  
hemodynamics characteristics of  
axial flow pumps, 24-25  
centrifugal pumps, 25  
displacement pumps, 25  
historical perspective of, 1-13  
immunobiologic consequences of, 127-141  
long-term, 52-55  
blood types and, 54  
diagnosis for, 54  
early management with, 80  
for right-sided circulatory failure, 53-54  
future directions in, 55  
indications for, 52  
institutional criteria for, 52-53  
myocardial recovery after, 79-84  
patient selection for, 54, 80  
preformed antibodies and, 54  
results with, 82-83  
size of, 54  
support for, 54-55  
valve prosthesis/intracardiac shunts, 53  
ventricular recovery assessment with,  
80-81  
weaning patient from, 81  
physiologic basis of, 15-24, 26  
ideal, 25-26  
interaction with native heart, 19-24  
aortic valve-VAD interaction, 21  
LVAD synchronization, 19-21

- mitral valve-VAD interaction, 21-23
- right heart-LVAD interaction, 23-24
- tricuspid valve-VAD interaction, 23
- of heart failure, 17-18
- of recovery, 18-19
- ventricular physiology, 15-17
- practitioner's role in, 97-98
- pulsatile left
  - development of, 2-6
- removal of
  - described, 81-82
  - rationale for, 75-76
- response to arrhythmias, 24
- response to congenital heart defects, 24
- response to coronary artery disease, 24
- short-term
  - devices in, 78
  - early management with, 77-78
  - for acute fulminant myocarditis, 79
  - for myocardial infarction, 79
  - for postcardiotomy cardiogenic shock, 78-79
  - insertion of, 76-77
  - myocardial recovery after
    - demonstration of, 77-78
  - patient selection for, 76
  - selection of, 76-77
- unanswered questions related to, 83-84

#### Ventricular remodeling

- heart failure progression and, 87-89. *See also* *Heart failure, progression of, left ventricular remodeling and.*

## W

- Warthin-Starry technique
  - in infective endocarditis diagnosis, 208

#### Weight

- excess
  - hypertriglyceridemia effects of, 422-423

#### Weight reduction

- in cardiovascular disease prevention, 475
- in hypertriglyceridemia management, 422-423

#### Wine

- biology of, 452-453
- in vascular biology, 453-454
- moderate consumption of
  - in cardiovascular disease prevention, 449-457

#### Work issues

- in outpatient management of patients on long-term assist devices, 101-102

#### Wound(s)

- management of
  - in outpatient management of patients on long-term assist devices, 99

## X

#### Xanthine oxidase

- as source of reactive oxygen species in vascular diseases, 295



